Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, GABA-A | 7 | 2022 | 624 | 1.100 |
Why?
|
| Cytochrome P-450 Enzyme System | 10 | 2005 | 423 | 1.090 |
Why?
|
| Cyclophosphamide | 9 | 2011 | 2228 | 0.880 |
Why?
|
| Killer Cells, Natural | 2 | 2024 | 2210 | 0.790 |
Why?
|
| Antineoplastic Agents, Alkylating | 8 | 2011 | 614 | 0.610 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2017 | 25 | 0.580 |
Why?
|
| Prodrugs | 8 | 2007 | 273 | 0.540 |
Why?
|
| Adenoviridae | 4 | 2010 | 1092 | 0.510 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 1347 | 0.440 |
Why?
|
| Triazines | 2 | 2009 | 307 | 0.430 |
Why?
|
| NADPH-Ferrihemoprotein Reductase | 6 | 2009 | 30 | 0.430 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 4 | 2007 | 246 | 0.390 |
Why?
|
| Interleukin-2 | 1 | 2017 | 1896 | 0.350 |
Why?
|
| Etomidate | 3 | 2018 | 185 | 0.330 |
Why?
|
| Steroid Hydroxylases | 2 | 2007 | 93 | 0.330 |
Why?
|
| Neoplasms | 10 | 2024 | 22340 | 0.320 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2008 | 15 | 0.320 |
Why?
|
| Gliosarcoma | 4 | 2007 | 116 | 0.310 |
Why?
|
| Ifosfamide | 4 | 2006 | 233 | 0.280 |
Why?
|
| Telomerase | 2 | 2010 | 749 | 0.280 |
Why?
|
| Hypnotics and Sedatives | 3 | 2019 | 1191 | 0.270 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 5501 | 0.270 |
Why?
|
| Locomotion | 2 | 2019 | 384 | 0.260 |
Why?
|
| Mice, SCID | 7 | 2017 | 2630 | 0.250 |
Why?
|
| Adenoviruses, Human | 1 | 2007 | 258 | 0.240 |
Why?
|
| HEK293 Cells | 7 | 2020 | 4260 | 0.240 |
Why?
|
| Signal Transduction | 2 | 2024 | 23601 | 0.220 |
Why?
|
| NADH, NADPH Oxidoreductases | 2 | 2000 | 96 | 0.210 |
Why?
|
| Oncolytic Virotherapy | 1 | 2008 | 520 | 0.210 |
Why?
|
| Virus Replication | 3 | 2010 | 2447 | 0.200 |
Why?
|
| Promoter Regions, Genetic | 3 | 2010 | 5786 | 0.200 |
Why?
|
| Gene Deletion | 1 | 2008 | 2666 | 0.180 |
Why?
|
| Gelatin | 1 | 2022 | 227 | 0.180 |
Why?
|
| Anesthetics, General | 2 | 2020 | 151 | 0.170 |
Why?
|
| Protein Subunits | 3 | 2022 | 939 | 0.170 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 2022 | 1140 | 0.170 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2018 | 3737 | 0.160 |
Why?
|
| Reflex, Righting | 1 | 2018 | 19 | 0.160 |
Why?
|
| Transfection | 3 | 2018 | 5743 | 0.150 |
Why?
|
| GABA Agonists | 1 | 2018 | 105 | 0.150 |
Why?
|
| Diphosphonates | 1 | 2023 | 625 | 0.150 |
Why?
|
| Radioligand Assay | 1 | 2018 | 364 | 0.140 |
Why?
|
| Cell Division | 3 | 2017 | 4475 | 0.140 |
Why?
|
| Gene Transfer Techniques | 2 | 2000 | 1216 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2017 | 3608 | 0.140 |
Why?
|
| Hydrogels | 1 | 2022 | 728 | 0.140 |
Why?
|
| Larva | 1 | 2018 | 511 | 0.130 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 379 | 0.130 |
Why?
|
| Barbiturates | 1 | 2016 | 113 | 0.130 |
Why?
|
| Osteogenesis | 1 | 2023 | 1282 | 0.130 |
Why?
|
| Genetic Vectors | 6 | 2010 | 3404 | 0.130 |
Why?
|
| Electrophysiological Phenomena | 1 | 2018 | 307 | 0.130 |
Why?
|
| Benzodiazepines | 1 | 2022 | 1136 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 5 | 2006 | 6113 | 0.120 |
Why?
|
| GABA Agents | 1 | 2015 | 40 | 0.120 |
Why?
|
| Retroviridae | 3 | 2006 | 847 | 0.120 |
Why?
|
| Coculture Techniques | 2 | 2017 | 1336 | 0.120 |
Why?
|
| Receptors, GABA | 1 | 2016 | 312 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2009 | 11868 | 0.120 |
Why?
|
| Anesthetics | 1 | 2019 | 525 | 0.110 |
Why?
|
| Protein Engineering | 1 | 2018 | 550 | 0.110 |
Why?
|
| Propofol | 1 | 2020 | 606 | 0.110 |
Why?
|
| Cell Survival | 1 | 2004 | 5747 | 0.110 |
Why?
|
| GABA-A Receptor Agonists | 1 | 2014 | 86 | 0.110 |
Why?
|
| Cell Line | 4 | 2017 | 15543 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2022 | 3513 | 0.110 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 1837 | 0.100 |
Why?
|
| Animals | 22 | 2023 | 168764 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2020 | 10729 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 938 | 0.100 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 17075 | 0.100 |
Why?
|
| Mice, Inbred ICR | 3 | 2007 | 339 | 0.100 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2022 | 1663 | 0.090 |
Why?
|
| Xenopus | 3 | 2020 | 709 | 0.090 |
Why?
|
| Rats | 8 | 2022 | 23707 | 0.090 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2010 | 81 | 0.090 |
Why?
|
| Kinetics | 1 | 2018 | 6274 | 0.090 |
Why?
|
| Antineoplastic Agents | 4 | 2005 | 13648 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2024 | 4752 | 0.080 |
Why?
|
| Models, Molecular | 2 | 2020 | 5379 | 0.080 |
Why?
|
| Oximetry | 1 | 2011 | 459 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 4850 | 0.070 |
Why?
|
| Transduction, Genetic | 2 | 2001 | 898 | 0.070 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2009 | 254 | 0.070 |
Why?
|
| Humans | 28 | 2024 | 765968 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2017 | 1510 | 0.070 |
Why?
|
| Binding Sites | 3 | 2022 | 6001 | 0.070 |
Why?
|
| Oncolytic Viruses | 1 | 2010 | 344 | 0.070 |
Why?
|
| Oxygen | 3 | 2011 | 4241 | 0.070 |
Why?
|
| Mice | 11 | 2023 | 81819 | 0.060 |
Why?
|
| DNA Primers | 2 | 2008 | 2825 | 0.060 |
Why?
|
| Allosteric Regulation | 2 | 2020 | 425 | 0.060 |
Why?
|
| Mucin-1 | 1 | 2010 | 531 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2019 | 14448 | 0.060 |
Why?
|
| Catalysis | 1 | 2006 | 770 | 0.060 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2004 | 110 | 0.050 |
Why?
|
| Alcian Blue | 1 | 2022 | 13 | 0.050 |
Why?
|
| Pregnancy | 1 | 2024 | 30260 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2010 | 2002 | 0.050 |
Why?
|
| Patch-Clamp Techniques | 2 | 2015 | 918 | 0.050 |
Why?
|
| Dental Pulp | 1 | 2022 | 80 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2006 | 8529 | 0.050 |
Why?
|
| Biotransformation | 1 | 2001 | 165 | 0.050 |
Why?
|
| Chondrogenesis | 1 | 2022 | 238 | 0.040 |
Why?
|
| Histamine | 1 | 2022 | 497 | 0.040 |
Why?
|
| Photochemical Processes | 1 | 2020 | 84 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2005 | 2230 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2022 | 8102 | 0.040 |
Why?
|
| Base Sequence | 2 | 2008 | 12403 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 2056 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 6069 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2B1 | 1 | 1998 | 22 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 1999 | 155 | 0.040 |
Why?
|
| Cryoelectron Microscopy | 1 | 2022 | 645 | 0.040 |
Why?
|
| Zebrafish | 2 | 2019 | 3036 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 1857 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2000 | 2014 | 0.030 |
Why?
|
| DNA Adducts | 1 | 1997 | 94 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 21056 | 0.030 |
Why?
|
| Glioma | 1 | 2011 | 3493 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2022 | 934 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2020 | 1885 | 0.030 |
Why?
|
| Xenopus laevis | 1 | 2019 | 964 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 2011 | 9071 | 0.030 |
Why?
|
| Protein Structure, Quaternary | 1 | 2016 | 423 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2023 | 2412 | 0.030 |
Why?
|
| Liver | 3 | 2007 | 7562 | 0.030 |
Why?
|
| Time Factors | 3 | 2009 | 40065 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2023 | 11641 | 0.030 |
Why?
|
| Carbazoles | 1 | 1997 | 229 | 0.030 |
Why?
|
| Ligands | 1 | 2022 | 3273 | 0.030 |
Why?
|
| Clone Cells | 1 | 1998 | 1672 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2015 | 6493 | 0.030 |
Why?
|
| Gene Expression | 3 | 2018 | 7584 | 0.030 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 852 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2019 | 1560 | 0.030 |
Why?
|
| Carcinogens | 1 | 1997 | 452 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 3051 | 0.030 |
Why?
|
| Drug Partial Agonism | 1 | 2014 | 24 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2006 | 5337 | 0.030 |
Why?
|
| Female | 6 | 2024 | 396112 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 1333 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2022 | 1855 | 0.020 |
Why?
|
| Anesthetics, Intravenous | 1 | 2015 | 397 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2015 | 1083 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 2207 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1998 | 4562 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2011 | 158 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 1997 | 1673 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 4209 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 2535 | 0.020 |
Why?
|
| Gene Order | 1 | 2010 | 164 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3946 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 1998 | 2394 | 0.020 |
Why?
|
| Male | 6 | 2018 | 363698 | 0.020 |
Why?
|
| Forecasting | 1 | 1999 | 2936 | 0.020 |
Why?
|
| Stem Cells | 1 | 2022 | 3540 | 0.020 |
Why?
|
| Body Weight | 1 | 2000 | 4622 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2022 | 18973 | 0.020 |
Why?
|
| Oocytes | 1 | 2014 | 1169 | 0.020 |
Why?
|
| Kidney | 1 | 2004 | 7066 | 0.020 |
Why?
|
| Poloxamer | 1 | 2007 | 56 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 9550 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 8041 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 10261 | 0.020 |
Why?
|
| Acetaldehyde | 1 | 2005 | 39 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2014 | 3634 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2005 | 614 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 18293 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2007 | 967 | 0.010 |
Why?
|
| Troleandomycin | 1 | 2003 | 2 | 0.010 |
Why?
|
| Cricetulus | 1 | 2005 | 805 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2005 | 562 | 0.010 |
Why?
|
| Procarbazine | 1 | 2003 | 172 | 0.010 |
Why?
|
| Apoptosis | 2 | 2010 | 9514 | 0.010 |
Why?
|
| Ketoconazole | 1 | 2003 | 93 | 0.010 |
Why?
|
| Microsomes, Liver | 1 | 2003 | 174 | 0.010 |
Why?
|
| Glutathione | 1 | 2005 | 588 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2003 | 461 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 1984 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 679 | 0.010 |
Why?
|
| Cricetinae | 1 | 2005 | 2411 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 4392 | 0.010 |
Why?
|
| Biological Transport | 1 | 2005 | 2081 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2003 | 608 | 0.010 |
Why?
|
| Dacarbazine | 1 | 2003 | 552 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2005 | 2218 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 1999 | 117 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2014 | 12768 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2003 | 963 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 2003 | 769 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2003 | 3586 | 0.010 |
Why?
|
| Prospective Studies | 1 | 1999 | 54802 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 1534 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 8611 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 1999 | 1744 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1997 | 1965 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 10429 | 0.010 |
Why?
|
| Protein Binding | 1 | 1999 | 9296 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 7478 | 0.000 |
Why?
|
| Adult | 1 | 1999 | 223044 | 0.000 |
Why?
|
Concepts
(201)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(16)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_